Fulltext

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Leyvraz, S. ; Piperno-Neumann, S. ; Suciu, S. ; Baurain, J. F. ; Zdzienicki, M. ; Testori, A. ; Marshall, E. ; Scheulen, M. ; Jouary, T. ; Negrier, S. ; Vermorken, J. B. ; Kaempgen, E. ; Durando, X. ; Schadendorf, D. ; Gurunath, R. Karra ; Keilholz, U.

In: Annals of Oncology, 2014, vol. 25, no. 3, p. 742-746

Zum persönliche Liste hinzufügen
    Titel
    • Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial
    Autor
    • Leyvraz, S.. Oncology Department, University Hospital, Lausanne, Switzerland
    • Piperno-Neumann, S.. Institut Curie, Paris, France
    • Suciu, S.. EORTC Headquarters, Brussels
    • Baurain, J. F.. Centre du Cancer, Cliniques Universitaires Saint-Luc, Brussels, Belgium
    • Zdzienicki, M.. Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Testori, A.. European Institute of Oncology, Milan, Italy
    • Marshall, E.. Clatterbridge Centre for Oncology, Wirral, UK
    • Scheulen, M.. West German Cancer Center, University of Essen Medical School, Essen, Germany
    • Jouary, T.. University Hospital Bordeaux Saint André, Bordeaux
    • Negrier, S.. Léon-Bérard Cancer Centre, Lyon, France
    • Vermorken, J. B.. Antwerp University Hospital, Edegem, Belgium
    • Kaempgen, E.. Universitätsklinik Erlangen, Erlangen, Germany
    • Durando, X.. Centre Jean Perrin, Clermont-Ferrand, France
    • Schadendorf, D.. University Hospital Essen, Essen
    • Gurunath, R. Karra. EORTC Headquarters, Brussels
    • Keilholz, U.. Department of Hematology and Medical Oncology, Charité, CBF, Berlin, Germany
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Annals of Oncology, 2014, vol. 25, no. 3, p. 742-746. Oxford University Press
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:300568
    Summary
    Despite an improved antitumor efficacy as noticed by an enhanced response rate and an improved progression-free survival, the hepatic intra-arterial fotemustine did not increase the overall survival of uveal melanoma patients with liver metastases only. We propose to consider intrahepatic treatment as an experimental approach